Skip to main content
. 2021 Oct 30;41(2):191–203. doi: 10.1038/s41388-021-02077-w

Fig. 8. A proposed model depicting the therapeutic mechanism of GRB7-PLK1 axis inhibition to overcome MEKi resistance in KRAS mutant colon cancer cells.

Fig. 8

A In KRAS mutant CRC cells, GRB7 confers MEKi resistance through mediating the RTK pathway. B Combination AZD6244 and GRB7-PLK1 axis inhibition significantly suppresses the proliferation and induces apoptosis through attenuating RTK signaling.